Alexa Fluor® 488 anti-PTEN Phospho (Ser380)
PTEN is a tumor suppressor gene which encodes a phosphatase that preferentially dephosphorylates phosphoinositide substrates and thereby modulates cell cycle progression and cell survival. PTEN is an important negative regulator of the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. PTEN is commonly mutated in human cancer, hence, loss of expression/function of PTEN due to mutations have been observed in prostate cancer, glioblastoma, endometrial, lung and breast cancers. Other non-cancerous clinical disorders associated with PTEN mutation are Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and proteus-like syndrome. PTEN is phosphorylated at several residues and some lead to increase in activity while others lead to loss of function and degradation. Specifically, phosphorylation at serine 380 residue by casein kinase 2 (CK2), leads to degradation of PTEN in the proteasome.
PRODUCT DETAILS
Clone: A22005D
Antibody Type: Monoclonal
Reactivity: Human
Format: Alexa Fluor 488
Host: Mouse
Isotype: IgG1, κ
Applications: ICFC - Quality tested IHC-P - Verified
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Original: $153.00
-70%$153.00
$45.90More Images
Alexa Fluor® 488 anti-PTEN Phospho (Ser380)
PTEN is a tumor suppressor gene which encodes a phosphatase that preferentially dephosphorylates phosphoinositide substrates and thereby modulates cell cycle progression and cell survival. PTEN is an important negative regulator of the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. PTEN is commonly mutated in human cancer, hence, loss of expression/function of PTEN due to mutations have been observed in prostate cancer, glioblastoma, endometrial, lung and breast cancers. Other non-cancerous clinical disorders associated with PTEN mutation are Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and proteus-like syndrome. PTEN is phosphorylated at several residues and some lead to increase in activity while others lead to loss of function and degradation. Specifically, phosphorylation at serine 380 residue by casein kinase 2 (CK2), leads to degradation of PTEN in the proteasome.
PRODUCT DETAILS
Clone: A22005D
Antibody Type: Monoclonal
Reactivity: Human
Format: Alexa Fluor 488
Host: Mouse
Isotype: IgG1, κ
Applications: ICFC - Quality tested IHC-P - Verified
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
PTEN is a tumor suppressor gene which encodes a phosphatase that preferentially dephosphorylates phosphoinositide substrates and thereby modulates cell cycle progression and cell survival. PTEN is an important negative regulator of the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. PTEN is commonly mutated in human cancer, hence, loss of expression/function of PTEN due to mutations have been observed in prostate cancer, glioblastoma, endometrial, lung and breast cancers. Other non-cancerous clinical disorders associated with PTEN mutation are Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and proteus-like syndrome. PTEN is phosphorylated at several residues and some lead to increase in activity while others lead to loss of function and degradation. Specifically, phosphorylation at serine 380 residue by casein kinase 2 (CK2), leads to degradation of PTEN in the proteasome.
PRODUCT DETAILS
Clone: A22005D
Antibody Type: Monoclonal
Reactivity: Human
Format: Alexa Fluor 488
Host: Mouse
Isotype: IgG1, κ
Applications: ICFC - Quality tested IHC-P - Verified
Regulatory Status: RUO
Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.
